Compass Therapeutics (NASDAQ:CMPX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02), FiscalAI reports.
Compass Therapeutics Price Performance
Shares of CMPX traded up $0.16 during mid-day trading on Friday, reaching $2.15. The company had a trading volume of 3,825,555 shares, compared to its average volume of 2,660,902. The company's 50-day moving average is $2.09 and its 200-day moving average is $3.86. Compass Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.88. The company has a market capitalization of $387.19 million, a P/E ratio of -5.37 and a beta of 0.92.
Wall Street Analyst Weigh In
CMPX has been the topic of several recent analyst reports. Citigroup reaffirmed a "market outperform" rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Wall Street Zen cut Compass Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, April 25th. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a "buy" rating and a $5.00 price target on the stock. Piper Sandler lifted their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $11.77.
Check Out Our Latest Analysis on Compass Therapeutics
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of CMPX. Invesco Ltd. grew its position in shares of Compass Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company's stock worth $343,000 after buying an additional 3,245 shares during the period. XTX Topco Ltd raised its stake in shares of Compass Therapeutics by 582.2% in the 4th quarter. XTX Topco Ltd now owns 115,634 shares of the company's stock valued at $621,000 after purchasing an additional 98,684 shares during the period. Ikarian Capital LLC bought a new stake in Compass Therapeutics in the 4th quarter valued at approximately $4,296,000. Virtus Investment Advisers LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $277,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Compass Therapeutics during the 4th quarter worth about $437,000. Institutional investors and hedge funds own 68.43% of the company's stock.
Compass Therapeutics Company Profile
(
Get Free Report)
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
